Opinion|Videos|October 18, 2024
Payer and Patient Education Considerations for SCLC
Key Takeaways
- Establishing clear communication with payers and providing comprehensive clinical evidence can facilitate medication access for SCLC patients.
- Utilizing educational materials from reputable cancer organizations and support groups enhances patient understanding of SCLC.
Panelists discuss how to effectively collaborate with payers to ensure access to necessary medications for patients with small cell lung cancer (SCLC), while also exploring best practices for patient education and identifying valuable resources to share with those diagnosed with SCLC.
Advertisement
Episodes in this series
What are best practices for working with payers to ensure that patients with small cell lung cancer (SCLC) get access to the necessary medications?
How do you educate patients about SCLC, and which resources do you find useful in sharing with patients?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5